| 1 |
Yip TC, Vilar-Gomez E, Petta S, Yilmaz Y, Wong GL, Adams LA, de Lédinghen V, Sookoian S, Wong VW. Geographical similarity and differences in the burden and genetic predisposition of NAFLD. Hepatology 2023;77:1404-27. [PMID: 36062393 DOI: 10.1002/hep.32774] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 2 |
Amini-salehi E, Hassanipour S, Joukar F, Daryagasht AA, Khosousi M, Sadat Aleali M, Ansar MM, Heidarzad F, Abdzadeh E, Vakilpour A, Mansour-ghanaei F. Risk Factors of Non-alcoholic Fatty Liver Disease in the Iranian Adult Population: A Systematic Review and Meta-analysis. Hepat Mon 2023;23. [DOI: 10.5812/hepatmon-131523] [Reference Citation Analysis]
|
| 3 |
Farah M, Anugwom C, Ferrer JD, Baca EL, Mattos AZ, Possebon JPP, Arrese M, Prieto J, Balderramo D, Carrera E, Debes JD. Changing epidemiology of hepatocellular carcinoma in South America: A report from the South American liver research network. Ann Hepatol 2023;28:100876. [PMID: 36400386 DOI: 10.1016/j.aohep.2022.100876] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 4 |
Vetrano E, Rinaldi L, Mormone A, Giorgione C, Galiero R, Caturano A, Nevola R, Marfella R, Sasso FC. Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies. Biomedicines 2023;11. [PMID: 36831004 DOI: 10.3390/biomedicines11020468] [Reference Citation Analysis]
|
| 5 |
van Kleef LA, Sonneveld MJ, Zhu F, Ikram MA, Kavousi M, de Knegt RJ. Liver stiffness is associated with excess mortality in the general population driven by heart failure: The Rotterdam Study. Liver Int 2023. [PMID: 36744819 DOI: 10.1111/liv.15538] [Reference Citation Analysis]
|
| 6 |
Åberg F, Britton A, Luukkonen PK. Changes over time in the Chronic Liver Disease risk score predict liver-related outcomes: longitudinal analysis of the Whitehall II study. Scand J Gastroenterol 2023;58:170-7. [PMID: 35989617 DOI: 10.1080/00365521.2022.2113130] [Reference Citation Analysis]
|
| 7 |
Trifan A, Muzica CM, Nastasa R, Zenovia S, Stratina E, Stafie R, Rotaru A, Singeap AM, Cojocariu C, Sfarti C, Girleanu I, Chiriac S, Cuciureanu T, Huiban L, Stanciu C. High prevalence of liver fibrosis among general population: a Romanian population-based study. Hepatol Commun 2023;7:e0032. [PMID: 36691959 DOI: 10.1097/HC9.0000000000000032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Julián MT, Ballesta S, Pera G, Pérez-Montes de Oca A, Soldevila B, Caballería L, Morillas R, Expósito C, Martínez-Escudé A, Puig-Domingo M, Franch-Nadal J, Torán P, Cusi K, Julve J, Mauricio D, Alonso N. Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study. Front Endocrinol (Lausanne) 2022;13:1051958. [PMID: 36714592 DOI: 10.3389/fendo.2022.1051958] [Reference Citation Analysis]
|
| 9 |
Geier A, Rau M, Pathil-Warth A, von der Ohe M, Schattenberg J, Dikopoulos N, Stein K, Serfert Y, Berg T, Buggisch P, Demir M, Roeb E, Wiebner B, Wedemeyer H, Zeuzem S, Hofmann WP. Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany - First data from the German NAFLD-Registry. Z Gastroenterol 2023;61:60-70. [PMID: 36623544 DOI: 10.1055/a-1986-7676] [Reference Citation Analysis]
|
| 10 |
Canivet CM, Boursier J. Screening for Liver Fibrosis in the General Population: Where Do We Stand in 2022? Diagnostics (Basel) 2022;13. [PMID: 36611384 DOI: 10.3390/diagnostics13010091] [Reference Citation Analysis]
|
| 11 |
Lampignano L, Niro A, Castellana F, Bortone I, Zupo R, Tirelli S, Tatoli R, Griseta C, De Nucci S, Sila A, De Pergola G, Conte C, Alessio G, Boscia F, Sborgia G, Giannelli G, Sardone R; Eye Clinic Research Group. Liver fibrosis and retinal features in an older Mediterranean population: Results from the Salus in Apulia study. Front Neurosci 2022;16:1048375. [PMID: 36590297 DOI: 10.3389/fnins.2022.1048375] [Reference Citation Analysis]
|
| 12 |
Rice BA, Naimi TS, Long MT. Nonheavy Alcohol Use Associates With Liver Fibrosis and Nonalcoholic Steatohepatitis in the Framingham Heart Study. Clin Gastroenterol Hepatol 2022:S1542-3565(22)01125-9. [PMID: 36503167 DOI: 10.1016/j.cgh.2022.10.039] [Reference Citation Analysis]
|
| 13 |
Ferraioli G, Roccarina D. Update on the role of elastography in liver disease. Therap Adv Gastroenterol 2022;15:17562848221140657. [PMID: 36506750 DOI: 10.1177/17562848221140657] [Reference Citation Analysis]
|
| 14 |
Pitisuttithum P, Treeprasertsuk S. Nonalcoholic fatty liver disease (NAFLD) among older adults. Portal Hypertension & Cirrhosis 2022. [DOI: 10.1002/poh2.31] [Reference Citation Analysis]
|
| 15 |
Allen M, Doran R, Brain D, Powell EE, O’beirne J, Valery PC, Barnett A, Hettiarachchi R, Hickman IJ, Kularatna S. A Discrete Choice Experiment to Elicit Preferences for a Liver Screening Programme in Queensland, Australia: A Mixed Methods Study to Select Attributes and Levels.. [DOI: 10.21203/rs.3.rs-2232430/v1] [Reference Citation Analysis]
|
| 16 |
Pérez-Montes de Oca A, Julián MT, Pera G, Caballería L, Morillas R, Torán P, Expósito C, Franch-Nadal J, Mauricio D, Alonso N. Dysglycemia in young women attenuates the protective effect against fatty liver disease. Front Endocrinol (Lausanne) 2022;13:971864. [PMID: 36479218 DOI: 10.3389/fendo.2022.971864] [Reference Citation Analysis]
|
| 17 |
Kalavalapalli S, Leiva EG, Lomonaco R, Chi X, Shrestha S, Dillard R, Budd J, Romero JP, Li C, Bril F, Samraj G, Pennington J, Townsend P, Orlando F, Shetty S, Mansour L, Silva-Sombra LR, Bedossa P, Malaty J, Barb D, Gurka MJ, Cusi K. Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients with Type 2 Diabetes and NAFLD. J Clin Endocrinol Metab 2022:dgac660. [PMID: 36378995 DOI: 10.1210/clinem/dgac660] [Reference Citation Analysis]
|
| 18 |
Chang X, Bian H, Xia M, Zhu X, Sun X, Yang X, Gao J, Lin H, Yan H, Gao X. Postprandial glucose is correlated with an increasing risk of liver fibrosis in Chinese patients with nonalcoholic fatty liver disease. Diabetes & Metabolism 2022;48:101377. [DOI: 10.1016/j.diabet.2022.101377] [Reference Citation Analysis]
|
| 19 |
Hamada Y, Hirano E. Regulation of Iron Metabolism in NAFLD/NASH. Non-alcoholic Fatty Liver Disease - New-Insight and Glance Into Disease Pathogenesis [Working Title] 2022. [DOI: 10.5772/intechopen.107221] [Reference Citation Analysis]
|
| 20 |
Jacobson IM, Wong VW, Castera L, Anstee QM, Noureddin M, Cusi K, Harrison SA, Bugianesi E, Younossi ZM. Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis. J Clin Gastroenterol 2023;57:253-64. [PMID: 36251413 DOI: 10.1097/MCG.0000000000001780] [Reference Citation Analysis]
|
| 21 |
Unalp-Arida A, Ruhl CE. Prepandemic Prevalence Estimates of Fatty Liver Disease and Fibrosis Defined by Liver Elastography in the United States. Dig Dis Sci 2022;:1-16. [PMID: 36173583 DOI: 10.1007/s10620-022-07707-1] [Reference Citation Analysis]
|
| 22 |
Cazac G, Lăcătușu C, Mihai C, Grigorescu E, Onofriescu A, Mihai B. Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes. Biomedicines 2022;10:2375. [DOI: 10.3390/biomedicines10102375] [Reference Citation Analysis]
|
| 23 |
Dunn W, Song X, Koestler D, Grdinovac K, Al-Hihi E, Chen J, Taylor R, Wilson J, Weinman SA. Patients with type 2 diabetes and elevated fibrosis-4 are under-referred to hepatology and have unrecognized hepatic decompensation. J Gastroenterol Hepatol 2022;37:1815-21. [PMID: 35613944 DOI: 10.1111/jgh.15900] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 24 |
Sun Y, Hong L, Huang Z, Wang L, Xiong Y, Zong S, Zhang R, Liu J, Zang S. Fibrosis Risk in Nonalcoholic Fatty Liver Disease Is Related to Chronic Kidney Disease in Older Type 2 Diabetes Patients. J Clin Endocrinol Metab 2022;107:e3661-9. [PMID: 35766414 DOI: 10.1210/clinem/dgac382] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 25 |
Castera L, Boursier J. Noninvasive Algorithms for the Case Finding of "At-Risk" Patients with NAFLD. Semin Liver Dis 2022;42:313-26. [PMID: 35835440 DOI: 10.1055/s-0042-1751081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 26 |
Åberg F, Luukkonen PK, But A, Salomaa V, Britton A, Petersen KM, Bojesen SE, Balling M, Nordestgaard BG, Puukka P, Männistö S, Lundqvist A, Perola M, Jula A, Färkkilä M. Development and validation of a model to predict incident chronic liver disease in the general population: The CLivD score. J Hepatol 2022;77:302-11. [PMID: 35271949 DOI: 10.1016/j.jhep.2022.02.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 27 |
Ciardullo S, Perseghin G. Prevalence of elevated liver stiffness in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis. Diabetes Research and Clinical Practice 2022. [DOI: 10.1016/j.diabres.2022.109981] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 28 |
Dai C, Fang T, Hung W, Tsai H, Tsai Y. The Determinants of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Biomedicines 2022;10:1487. [DOI: 10.3390/biomedicines10071487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 29 |
Kechagias S, Ekstedt M, Simonsson C, Nasr P. Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. Hormones (Athens) 2022. [PMID: 35661987 DOI: 10.1007/s42000-022-00377-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 30 |
Park J, Kwon H, Sohn W, Cho J, Park SJ, Chang Y, Ryu S, Kim BI, Cho YK. Risk of liver fibrosis in patients with prediabetes and diabetes mellitus. PLoS ONE 2022;17:e0269070. [DOI: 10.1371/journal.pone.0269070] [Reference Citation Analysis]
|
| 31 |
Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol 2022;76:1362-78. [PMID: 35589256 DOI: 10.1016/j.jhep.2022.03.026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 32 |
Chen X, Wen H, Li Q, Shen L, Luo X, Zhou B, Guo R. Quantification of liver fat deposition in obese and diabetic patients: A pilot study on the correlation with myocardium and periapical fat content☆. Liver Research 2022. [DOI: 10.1016/j.livres.2022.05.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 33 |
Thévenot T, Vendeville S, Weil D, Akkouche L, Calame P, Canivet CM, Vanlemmens C, Richou C, Cervoni JP, Seronde MF, Di Martino V, Boursier J. Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study. PLoS One 2022;17:e0266965. [PMID: 35617294 DOI: 10.1371/journal.pone.0266965] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 34 |
Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 2022;28:528-62. [PMID: 35569886 DOI: 10.1016/j.eprac.2022.03.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 25.0] [Reference Citation Analysis]
|
| 35 |
Unalp-arida A, Ruhl CE. Prepandemic prevalence estimates of fatty liver disease and fibrosis defined by liver elastography in the United States.. [DOI: 10.1101/2022.04.05.22273458] [Reference Citation Analysis]
|
| 36 |
Han E, Huh JH, Lee EY, Bae JC, Chun SW, Yu SH, Kwak SH, Park KS, Lee BW. Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial. Diabetes Obes Metab 2022;24:752-6. [PMID: 34918436 DOI: 10.1111/dom.14623] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 37 |
Canivet CM, Smati S, Lannes A, Brisseau J, Judon L, Roch ML, Cariou B, Bellanger W, Guerci B, Boursier J. Awareness of chronic liver diseases, a comparison between diabetologists and general practitioners. Clin Res Hepatol Gastroenterol 2022;46:101848. [PMID: 34922062 DOI: 10.1016/j.clinre.2021.101848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 38 |
Unalp-Arida A, Ruhl CE. Transient Elastography-Assessed Hepatic Steatosis and Fibrosis Are Associated With Body Composition in the United States. Clin Gastroenterol Hepatol 2022;20:e808-30. [PMID: 33549867 DOI: 10.1016/j.cgh.2021.02.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 39 |
Nobarani S, Alaei-Shahmiri F, Aghili R, Malek M, Poustchi H, Lahouti M, Khamseh ME. Visceral Adipose Tissue and Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes. Dig Dis Sci 2022;67:1389-98. [PMID: 33788095 DOI: 10.1007/s10620-021-06953-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 40 |
Wensink D, Coenen S, Wilson JHP, Wagenmakers MAEM, Langendonk JG. Liver involvement in patients with erythropoietic protoporphyria. Dig Liver Dis 2022;54:515-20. [PMID: 34475006 DOI: 10.1016/j.dld.2021.08.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 41 |
Mirarchi L, Amodeo S, Citarrella R, Licata A, Soresi M, Giannitrapani L. SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. IJMS 2022;23:3668. [DOI: 10.3390/ijms23073668] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 42 |
Nabi O, Boursier J, Lapidus N, Mathurin P, de Ledinghen V, Petit JM, Goldberg M, Zins M, Lacombe K, Serfaty L. The burden of NAFLD in type 2 diabetic subjects from the general population: A Nationwide population-based follow-up study (NASHCO). Liver Int 2022;42:595-606. [PMID: 35066992 DOI: 10.1111/liv.15171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 43 |
Gluvic Z, Tomasevic R, Bojovic K, Obradovic M, Isenovic ER. Non-alcoholic fatty liver disease: a multidisciplinary clinical practice approach—the institutional adaptation to existing Clinical Practice Guidelines. Emergency and Critical Care Medicine 2022;2:12-22. [DOI: 10.1097/ec9.0000000000000016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 44 |
Lorena M, Bellan M, Lepore M, Sola D, Pedrazzoli R, Rigamonti C, De Benedittis C, Manfredi GF, Acquaviva A, Tonello S, Rizzi M, Minisini R, Pirisi M, Sainaghi PP. Clinical Relevance of Liver Involvement in the Clinical Course of Systemic Sclerosis. JCM 2022;11:966. [DOI: 10.3390/jcm11040966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 45 |
Parikh NS, Kamel H, Zhang C, Kumar S, Rosenblatt R, Spincemaille P, Gupta A, Cohen DE, de Leon MJ, Gottesman RF, Iadecola C. Association between Liver Fibrosis and Incident Dementia in the UK Biobank Study.. [DOI: 10.1101/2022.02.09.22270729] [Reference Citation Analysis]
|
| 46 |
Schwartz S, Lucas J, DeLegge MH. Non-alcoholic Steatohepatitis: From Pathophysiology to Clinical Practice. touchREV Endocrinol 2021;17:112-20. [PMID: 35118457 DOI: 10.17925/EE.2021.17.2.112] [Reference Citation Analysis]
|
| 47 |
Mallet V, Parlati L, Martinino A, Scarano Pereira JP, Jimenez CN, Sakka M, Bouam S, Retbi A, Krasteva D, Meritet JF, Schwarzinger M, Thabut D, Rufat P, Bonnefont-Rousselot D, Sogni P, Pol S, Tsochatzis E; Demosthenes research group. Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. J Hepatol 2022;76:265-74. [PMID: 34606913 DOI: 10.1016/j.jhep.2021.09.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 48 |
Yang S, Cheng J, Zhang R, Sun H, Zhang H, Lyu S, Duan W. Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population. Hepatol Res 2022;52:176-86. [PMID: 34751487 DOI: 10.1111/hepr.13728] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 49 |
Hu C, Zhuang X, Zhang J, Wang T, Du S, Wang J, Peng X, Cao Q, Zhang M, Jiang Y. Serum Metabolomics in Patients with Coexisting NAFLD and T2DM Using Liquid Chromatography-Mass Spectrometry. Lab Med 2022:lmab118. [PMID: 35075477 DOI: 10.1093/labmed/lmab118] [Reference Citation Analysis]
|
| 50 |
Wang X, Wu S, Yuan X, Chen S, Fu Q, Sun Y, Lan Y, Hu S, Wang Y, Lu Y, Qu S, Wang L. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study. The Journal of Clinical Endocrinology & Metabolism 2022;107:e745-e755. [DOI: 10.1210/clinem/dgab644] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 51 |
Ginès P, Castera L, Lammert F, Graupera I, Serra-Burriel M, Allen AM, Wong VW, Hartmann P, Thiele M, Caballeria L, de Knegt RJ, Grgurevic I, Augustin S, Tsochatzis EA, Schattenberg JM, Guha IN, Martini A, Morillas RM, Garcia-Retortillo M, de Koning HJ, Fabrellas N, Pich J, Ma AT, Diaz MA, Roulot D, Newsome PN, Manns M, Kamath PS, Krag A; LiverScreen Consortium Investigators. Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology 2022;75:219-28. [PMID: 34537988 DOI: 10.1002/hep.32163] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 45.0] [Reference Citation Analysis]
|
| 52 |
Yanavich C, Perazzo H, Li F, Tobin N, Lee D, Zabih S, Morata M, Almeida C, Veloso VG, Grinsztejn B, Aldrovandi GM. A pilot study of microbial signatures of liver disease in those with HIV mono-infection in Rio de Janeiro, Brazil. AIDS 2022;36:49-58. [PMID: 34873092 DOI: 10.1097/QAD.0000000000003084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 53 |
Boursier J, Guillaume M, Bouzbib C, Lannes A, Pais R, Smatti S, Cariou B, Bureau C, Ganne-Carrié N, Bourlière M, de Lédinghen V. Non-invasive diagnosis and follow-up of non-alcoholic fatty liver disease. Clin Res Hepatol Gastroenterol 2022;46:101769. [PMID: 34332133 DOI: 10.1016/j.clinre.2021.101769] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 54 |
Chhabra S, Singh SP, Singh A, Mehta V, Kaur A, Bansal N, Sood A. Diabetes Mellitus Increases the Risk of Significant Hepatic Fibrosis in Patients With Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol 2022;12:409-16. [PMID: 35535092 DOI: 10.1016/j.jceh.2021.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 55 |
Apostolopoulou M, Roden M. Therapie von Begleiterkrankungen: Diabetes mellitus und Dyslipoproteinämie. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_20] [Reference Citation Analysis]
|
| 56 |
Karlas T. Diagnostik: Elastometrie. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_12] [Reference Citation Analysis]
|
| 57 |
Khlynova OV, Liu KM. Comorbidity of NAFLD and GERD as a cardiometabolic phenomenon. jour 2021. [DOI: 10.31146/1682-8658-ecg-194-10-49-54] [Reference Citation Analysis]
|
| 58 |
Nastasa R, Stanciu C, Zenovia S, Singeap AM, Cojocariu C, Sfarti C, Girleanu I, Chiriac S, Cuciureanu T, Huiban L, Muzica CM, Trifan A. The Prevalence of Liver Steatosis and Fibrosis Assessed by Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter in Apparently Healthy Romanian Medical Students. Diagnostics (Basel) 2021;11. [PMID: 34943578 DOI: 10.3390/diagnostics11122341] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 59 |
Dobbie LJ, Kassab M, Davison AS, Grace P, Cuthbertson DJ, Hydes TJ. Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care. J Clin Med 2021;10:5755. [PMID: 34945051 DOI: 10.3390/jcm10245755] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 60 |
Kuchay MS, Choudhary NS, Gagneja S, Mathew A, Bano T, Kaur P, Bahadur B, Singh MK, Gill HK, Wasir JS, Sud R, Mishra SK. Low skeletal muscle mass is associated with liver fibrosis in individuals with type 2 diabetes and nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2021;36:3204-11. [PMID: 34160089 DOI: 10.1111/jgh.15595] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 61 |
van Dijk AM, Schattenberg JM, Holleboom AG, Tushuizen ME. Referral care paths for non-alcoholic fatty liver disease-Gearing up for an ever more prevalent and severe liver disease. United European Gastroenterol J 2021;9:903-9. [PMID: 34609086 DOI: 10.1002/ueg2.12150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 62 |
Barb D, Repetto EM, Stokes ME, Shankar SS, Cusi K. Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease. Obesity (Silver Spring) 2021;29:1950-60. [PMID: 34553836 DOI: 10.1002/oby.23263] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 63 |
Pennisi G, Di Marco V, Buscemi C, Mazzola G, Randazzo C, Spatola F, Craxì A, Buscemi S, Petta S. Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population. J Gastroenterol Hepatol 2021;36:2389-96. [PMID: 33871081 DOI: 10.1111/jgh.15523] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 64 |
Ciardullo S, Monti T, Grassi G, Mancia G, Perseghin G. Blood pressure, glycemic status and advanced liver fibrosis assessed by transient elastography in the general United States population. J Hypertens 2021;39:1621-7. [PMID: 33657584 DOI: 10.1097/HJH.0000000000002835] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 65 |
Alam MS, Kamrul-Hasan ABM, Kalam ST, Rahman SMM, Hoque MI, Islam MB, Paul AK. Liver Stiffness Measurement by Using Transient Elastography in Bangladeshi Patients with Type 2 Diabetes Mellitus and Ultrasonography-Diagnosed Nonalcoholic Fatty Liver Disease. Diabetes Metab Syndr Obes 2021;14:3089-96. [PMID: 34262313 DOI: 10.2147/DMSO.S317876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 66 |
Castera L. Screening for liver fibrosis in primary care: Focus on subjects above 40 and with metabolic risk factors. United European Gastroenterol J 2021. [PMID: 34228905 DOI: 10.1002/ueg2.12120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 67 |
Kuchay MS, Choudhary NS, Mishra SK, Bano T, Gagneja S, Mathew A, Singh MK, Kaur P, Gill HK, Wasir JS, Sud R, Mithal A. Prevalence of clinically relevant liver fibrosis due to nonalcoholic fatty liver disease in Indian individuals with type 2 diabetes. JGH Open 2021;5:915-22. [PMID: 34386600 DOI: 10.1002/jgh3.12606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 68 |
Foschi FG, Domenicali M, Giacomoni P, Dall'Aglio AC, Conti F, Borghi A, Bevilacqua V, Napoli L, Mirici F, Cucchetti A, Ercolani G, Gardini AC, Bellentani S, Gastaldelli A, Giuffrè M, Tiribelli C, Bedogni G; Bagnacavallo Study Group. Is there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population? Ann Hepatol 2020;19:380-7. [PMID: 32451205 DOI: 10.1016/j.aohep.2020.04.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 69 |
García-Carretero R, Holgado-Cuadrado R, Barquero-Pérez Ó. Assessment of Classification Models and Relevant Features on Nonalcoholic Steatohepatitis Using Random Forest. Entropy (Basel) 2021;23:763. [PMID: 34204225 DOI: 10.3390/e23060763] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 70 |
Llop E, Iruzubieta P, Perelló C, Fernández Carrillo C, Cabezas J, Escudero MD, González M, Hernández Conde M, Puchades L, Arias-Loste MT, Serra MÁ, Crespo J, Calleja JL. High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort. United European Gastroenterol J 2021. [PMID: 34077628 DOI: 10.1002/ueg2.12109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 71 |
Hartl L, Elias J, Prager G, Reiberger T, Unger LW. Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. World J Gastroenterol 2021; 27(19): 2281-2298 [PMID: 34040322 DOI: 10.3748/wjg.v27.i19.2281] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 72 |
Nagappa B, Ramalingam A, Rastogi A, Dubey S, Thomas SS, Gupta E, Sarin SK. Number needed to screen to prevent progression of liver fibrosis to cirrhosis at primary health centers: An experience from Delhi. J Family Med Prim Care 2021;10:1412-8. [PMID: 34041187 DOI: 10.4103/jfmpc.jfmpc_1441_20] [Reference Citation Analysis]
|
| 73 |
Li S, Lu J, Gu G, Bai W, Ye Y, Bao Y, Yu H, Han J. Serum Creatinine-to-Cystatin C Ratio in the Progression Monitoring of Non-alcoholic Fatty Liver Disease. Front Physiol 2021;12:664100. [PMID: 33935810 DOI: 10.3389/fphys.2021.664100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 74 |
Heiningen JS, den Hoed C, Bindels P, Elshout G. Echografische leververvetting. Huisarts Wet 2021;64:40-43. [DOI: 10.1007/s12445-021-1045-y] [Reference Citation Analysis]
|
| 75 |
Alferink LJM, Radjabzadeh D, Erler NS, Vojinovic D, Medina-Gomez C, Uitterlinden AG, de Knegt RJ, Amin N, Ikram MA, Janssen HLA, Kiefte-de Jong JC, Metselaar HJ, van Duijn CM, Kraaij R, Darwish Murad S. Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Population-Based Study of 1,355 Adults. Hepatology 2021;73:968-82. [PMID: 32530501 DOI: 10.1002/hep.31417] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 76 |
Zhang X, Mens MMJ, Abozaid YJ, Bos D, Darwish Murad S, de Knegt RJ, Ikram MA, Pan Q, Ghanbari M. Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study. Aliment Pharmacol Ther 2021;53:432-42. [PMID: 33244812 DOI: 10.1111/apt.16177] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
|
| 77 |
Lomonaco R, Godinez Leiva E, Bril F, Shrestha S, Mansour L, Budd J, Portillo Romero J, Schmidt S, Chang KL, Samraj G, Malaty J, Huber K, Bedossa P, Kalavalapalli S, Marte J, Barb D, Poulton D, Fanous N, Cusi K. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Diabetes Care 2021;44:399-406. [PMID: 33355256 DOI: 10.2337/dc20-1997] [Cited by in Crossref: 99] [Cited by in F6Publishing: 92] [Article Influence: 49.5] [Reference Citation Analysis]
|
| 78 |
Long MT, Zhang X, Xu H, Liu CT, Corey KE, Chung RT, Loomba R, Benjamin EJ. Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. Hepatology 2021;73:548-59. [PMID: 33125745 DOI: 10.1002/hep.31608] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 79 |
Boursier J, Tsochatzis EA. Case-finding strategies in non-alcoholic fatty liver disease. JHEP Rep 2021;3:100219. [PMID: 33659890 DOI: 10.1016/j.jhepr.2020.100219] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 80 |
Park H, Jun DW, Park HK, Kim M. Clinical implications of serum Mac-2-binding protein glycan isomer as a novel biomarker of advanced hepatic fibrosis in diabetes. Ann Transl Med 2020;8:1583. [PMID: 33437782 DOI: 10.21037/atm-20-5216] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 81 |
Conway RBN, Sudenga S, McClain D, Blot WJ. Diabetes and liver cancer risk: A stronger effect in Whites than Blacks? J Diabetes Complications 2021;35:107816. [PMID: 33323327 DOI: 10.1016/j.jdiacomp.2020.107816] [Reference Citation Analysis]
|
| 82 |
Schröder B, Roden M. Was bedeuten die neuen Diabetessubgruppen für Menschen mit Fettlebererkrankung? Diabetologe 2021;17:20-5. [DOI: 10.1007/s11428-020-00698-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 83 |
Watt GP, De La Cerda I, Pan JJ, Fallon MB, Beretta L, Loomba R, Lee M, McCormick JB, Fisher-Hoch SP. Elevated Glycated Hemoglobin Is Associated With Liver Fibrosis, as Assessed by Elastography, in a Population-Based Study of Mexican Americans. Hepatol Commun 2020;4:1793-801. [PMID: 33305150 DOI: 10.1002/hep4.1603] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 84 |
Acierno C, Caturano A, Pafundi PC, Nevola R, Adinolfi LE, Sasso FC. Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin. Exploration of Medicine 2020;1. [DOI: 10.37349/emed.2020.00019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 85 |
Chen TP, Lai M, Lin WY, Huang KC, Yang KC. Metabolic profiles and fibrosis of nonalcoholic fatty liver disease in the elderly: A community-based study. J Gastroenterol Hepatol 2020;35:1636-43. [PMID: 32333452 DOI: 10.1111/jgh.15073] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 86 |
Mikolasevic I, Domislovic V, Turk Wensveen T, Delija B, Klapan M, Juric T, Lukic A, Mijic A, Skenderevic N, Puz P, Ostojic A, Krznaric Z, Radic-Kristo D, Filipec Kanizaj T, Stimac D. Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study. Eur J Intern Med 2020;82:68-75. [PMID: 32839076 DOI: 10.1016/j.ejim.2020.08.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 87 |
Chen K, Sng WK, Quah JH, Liu J, Chong BY, Lee HK, Wang XF, Tan NC, Chang PE, Tan HC, Bee YM, Goh GBB. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus.PLoS One. 2020;15:e0236977. [PMID: 32822391 DOI: 10.1371/journal.pone.0236977] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 88 |
Nabi O, Lacombe K, Boursier J, Mathurin P, Zins M, Serfaty L. Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in General Population: the French Nationwide NASH-CO Study. Gastroenterology 2020;159:791-793.e2. [PMID: 32376412 DOI: 10.1053/j.gastro.2020.04.048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 89 |
Vali Y, Lee J, Boursier J, Spijker R, Löffler J, Verheij J, Brosnan MJ, Böcskei Z, Anstee QM, Bossuyt PM, Zafarmand MH; LITMUS systematic review team(†). Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. J Hepatol 2020;73:252-62. [PMID: 32275982 DOI: 10.1016/j.jhep.2020.03.036] [Cited by in Crossref: 108] [Cited by in F6Publishing: 107] [Article Influence: 36.0] [Reference Citation Analysis]
|
| 90 |
A Abdel Jaleel G, A Al-Awdan S, F Ahmed R, A H Ahmed-Farid O, Saleh DO. Melatonin regulates neurodegenerative complications associated with NAFLD via enhanced neurotransmission and cellular integrity: a correlational study. Metab Brain Dis 2020;35:1251-61. [PMID: 32696189 DOI: 10.1007/s11011-020-00593-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 91 |
Parikh NS, Kumar S, Rosenblatt R, Zhao C, Cohen DE, Iadecola C, Kamel H. Association between liver fibrosis and cognition in a nationally representative sample of older adults. Eur J Neurol 2020;27:1895-903. [DOI: 10.1111/ene.14384] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 92 |
Hydes TJ, Summers N, Brown E, Alam U, Thomaides-Brears H, Wilding JPH, Cuthbertson DJ. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes. Diabet Med 2020;37:1793-806. [PMID: 32619031 DOI: 10.1111/dme.14356] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 93 |
Dewidar B, Kahl S, Pafili K, Roden M. Metabolic liver disease in diabetes - From mechanisms to clinical trials. Metabolism 2020;111S:154299. [PMID: 32569680 DOI: 10.1016/j.metabol.2020.154299] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 15.3] [Reference Citation Analysis]
|
| 94 |
Zhang Q, Niu X, Tian L, Liu J, Niu R, Quan J, Yu J, Lin W, Qian Z, Zeng P. CTRP13 attenuates the expression of LN and CAV-1 Induced by high glucose via CaMKKβ/AMPK pathway in rLSECs. Aging (Albany NY) 2020;12:11485-99. [PMID: 32554851 DOI: 10.18632/aging.103234] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 95 |
Pielok A, Marycz K. Non-Coding RNAs as Potential Novel Biomarkers for Early Diagnosis of Hepatic Insulin Resistance. Int J Mol Sci 2020;21:E4182. [PMID: 32545342 DOI: 10.3390/ijms21114182] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 96 |
Harris R, West J, Morling JR. Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world? Aliment Pharmacol Ther 2020;51:1199-200. [PMID: 32424922 DOI: 10.1111/apt.15714] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 97 |
Fujii H, Kawada N, Japan Study Group Of Nafld Jsg-Nafld. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E3863. [PMID: 32485838 DOI: 10.3390/ijms21113863] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 98 |
Shaheen AA, Riazi K, Medellin A, Bhayana D, Kaplan GG, Jiang J, Park R, Schaufert W, Burak KW, Sargious M, Swain MG. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study. CMAJ Open 2020;8:E370-6. [PMID: 32414883 DOI: 10.9778/cmajo.20200009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 99 |
Rhee EJ. Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective. Endocrinol Metab (Seoul) 2019;34:226-33. [PMID: 31565874 DOI: 10.3803/EnM.2019.34.3.226] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 12.7] [Reference Citation Analysis]
|
| 100 |
Unalp-arida A, Ruhl CE. Transient elastography assessed hepatic steatosis and fibrosis are associated with body composition in the United States.. [DOI: 10.1101/2020.05.01.20087510] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 101 |
García-Compeán D, Villarreal-Pérez JZ, Cavazos MEO, Lavalle-Gonzalez FJ, Borjas-Almaguer OD, Del Cueto-Aguilera AN, González-González JA, Treviño-Garza C, Huerta-Pérez L, Maldonado-Garza HJ. Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening? Ann Hepatol 2020;19:258-64. [PMID: 32063504 DOI: 10.1016/j.aohep.2020.01.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 102 |
Alferink LJM, Erler NS, de Knegt RJ, Janssen HLA, Metselaar HJ, Darwish Murad S, Kiefte-de Jong JC. Adherence to a plant-based, high-fibre dietary pattern is related to regression of non-alcoholic fatty liver disease in an elderly population. Eur J Epidemiol 2020;35:1069-85. [PMID: 32323115 DOI: 10.1007/s10654-020-00627-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 103 |
Brain D, O'Beirne J, Hickman IJ, Powell EE, Valery PC, Kularatna S, Tulleners R, Farrington A, Horsfall L, Barnett A. Protocol for a randomised trial testing a community fibrosis assessment service for patients with suspected non-alcoholic fatty liver disease: LOCal assessment and triage evaluation of non-alcoholic fatty liver disease (LOCATE-NAFLD). BMC Health Serv Res 2020;20:335. [PMID: 32316984 DOI: 10.1186/s12913-020-05233-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 104 |
Lee YH, Cho Y, Lee BW, Park CY, Lee DH, Cha BS, Rhee EJ. Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis. Diabetes Metab J. 2019;43:31-45. [PMID: 30793550 DOI: 10.4093/dmj.2019.0011] [Cited by in Crossref: 69] [Cited by in F6Publishing: 73] [Article Influence: 23.0] [Reference Citation Analysis]
|
| 105 |
Sporea I, Mare R, Popescu A, Nistorescu S, Baldea V, Sirli R, Braha A, Sima A, Timar R, Lupusoru R. Screening for Liver Fibrosis and Steatosis in a Large Cohort of Patients with Type 2 Diabetes Using Vibration Controlled Transient Elastography and Controlled Attenuation Parameter in a Single-Center Real-Life Experience. J Clin Med 2020;9:E1032. [PMID: 32268517 DOI: 10.3390/jcm9041032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 106 |
Livzan MA, Gaus OV, Nikolaev NA, Krolevetz TS. NAFLD: comorbidity and associated diseases. jour 2020;1:57-65. [DOI: 10.31146/1682-8658-ecg-170-10-57-65] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 107 |
Patel PJ, Cheng JC, Banh X, Gracen L, Radford-Smith D, Hossain F, Horsfall LU, Hayward KL, Williams S, Johnson T, Brown NN, Saad N, Stuart KA, Russell AW, Valery PC, Clouston AD, Irvine KM, Bernard A, Powell EE. Clinically Significant Fibrosis Is Associated With Longitudinal Increases in Fibrosis-4 and Nonalcoholic Fatty Liver Disease Fibrosis Scores. Clin Gastroenterol Hepatol 2020;18:710-718.e4. [PMID: 31352092 DOI: 10.1016/j.cgh.2019.07.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 108 |
Jun DW, Nguyen MH. Editorial: choosing an appropriate risk stratification tool for nonalcoholic fatty liver disease-one size does not fit all. Authors' reply. Aliment Pharmacol Ther 2020;51:662-3. [PMID: 32100348 DOI: 10.1111/apt.15651] [Reference Citation Analysis]
|
| 109 |
Muthiah MD, Sanyal AJ. Burden of Disease due to Nonalcoholic Fatty Liver Disease. Gastroenterol Clin North Am 2020;49:1-23. [PMID: 32033757 DOI: 10.1016/j.gtc.2019.09.007] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 14.7] [Reference Citation Analysis]
|
| 110 |
Shaheen AA, Swain MG. Editorial: choosing an appropriate risk stratification tool for nonalcoholic fatty liver disease-one size does not fit all. Aliment Pharmacol Ther 2020;51:661-2. [PMID: 32100347 DOI: 10.1111/apt.15640] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 111 |
Fang C, Lim A, Sidhu PS. Ultrasound-based liver elastography in the assessment of fibrosis. Clin Radiol 2020;75:822-31. [PMID: 32067699 DOI: 10.1016/j.crad.2020.01.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 112 |
Yamamura S, Kawaguchi T, Nakano D, Tomiyasu Y, Yoshinaga S, Doi Y, Takahashi H, Anzai K, Eguchi Y, Torimura T, Shiba N. Profiles of advanced hepatic fibrosis evaluated by FIB‐4 index and shear wave elastography in health checkup examinees. Hepatol Res 2020;50:199-213. [DOI: 10.1111/hepr.13436] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 113 |
Kang KA, Jun DW, Kim MS, Kwon HJ, Nguyen MH. Prevalence of significant hepatic fibrosis using magnetic resonance elastography in a health check-up clinic population. Aliment Pharmacol Ther 2020;51:388-96. [PMID: 31943268 DOI: 10.1111/apt.15626] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 114 |
Umetsu S, Mizukami H, Saito T, Uchida C, Igawa A, Kudo K, Itabashi C, Osonoi S, Danyang G, Sasaki T, Yagihashi S, Hakamada K. Diabetes, an independent poor prognostic factor of non-B non-C hepatocellular carcinoma, correlates with dihydropyrimidinase-like 3 promoter methylation. Sci Rep 2020;10:1156. [PMID: 31980687 DOI: 10.1038/s41598-020-57883-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 115 |
Grgurevic I, Podrug K, Mikolasevic I, Kukla M, Madir A, Tsochatzis EA. Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach. Can J Gastroenterol Hepatol 2020;2020:9181368. [PMID: 32051820 DOI: 10.1155/2020/9181368] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 116 |
Liu J, Lahousse L, Nivard MG, Bot M, Chen L, van Klinken JB, Thesing CS, Beekman M, van den Akker EB, Slieker RC, Waterham E, van der Kallen CJH, de Boer I, Li-Gao R, Vojinovic D, Amin N, Radjabzadeh D, Kraaij R, Alferink LJM, Murad SD, Uitterlinden AG, Willemsen G, Pool R, Milaneschi Y, van Heemst D, Suchiman HED, Rutters F, Elders PJM, Beulens JWJ, van der Heijden AAWA, van Greevenbroek MMJ, Arts ICW, Onderwater GLJ, van den Maagdenberg AMJM, Mook-Kanamori DO, Hankemeier T, Terwindt GM, Stehouwer CDA, Geleijnse JM, 't Hart LM, Slagboom PE, van Dijk KW, Zhernakova A, Fu J, Penninx BWJH, Boomsma DI, Demirkan A, Stricker BHC, van Duijn CM. Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug-metabolite atlas. Nat Med 2020;26:110-7. [PMID: 31932804 DOI: 10.1038/s41591-019-0722-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 117 |
Roulot D. Screening for Liver Fibrosis in General or At-Risk Populations Using Transient Elastography. Liver Elastography 2020. [DOI: 10.1007/978-3-030-40542-7_47] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 118 |
Margalit M, Yeshua H, Gotlieb N, Zelber-sagi S. Detection of NAFLD/NASH in the General Population and in Primary Care Clinics. NAFLD and NASH 2020. [DOI: 10.1007/978-3-030-37173-9_2] [Reference Citation Analysis]
|
| 119 |
Motta BM, Grander C, Gögele M, Foco L, Vukovic V, Melotti R, Fuchsberger C, De Grandi A, Cantaloni C, Picard A, Mascalzoni D, Rossini A, Pattaro C, Tilg H, Pramstaller PP. Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study. J Transl Med 2019;17:408. [PMID: 31801616 DOI: 10.1186/s12967-019-02130-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 120 |
Koc AS, Sumbul HE. Prediabetes Is Associated With Increased Liver Stiffness Identified by Noninvasive Liver Fibrosis Assessment: ElastPQ Ultrasound Shear Wave Elastography Study. Ultrasound Quarterly 2019;35:330-8. [DOI: 10.1097/ruq.0000000000000419] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 121 |
Guillaume M, Moal V, Delabaudiere C, Zuberbuhler F, Robic MA, Lannes A, Metivier S, Oberti F, Gourdy P, Fouchard-Hubert I, Selves J, Michalak S, Peron JM, Cales P, Bureau C, Boursier J. Direct comparison of the specialised blood fibrosis tests FibroMeter(V2G) and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres. Aliment Pharmacol Ther 2019;50:1214-22. [PMID: 31617224 DOI: 10.1111/apt.15529] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 122 |
Akhmedov VA. Nonalcoholic fatty liver diseases as dramatic consequence of obesity. Medicinskij alfavit 2019;3:37-40. [DOI: 10.33667/2078-5631-2019-2-20(395)-37-40] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 123 |
A. Sherif Z. The Rise in the Prevalence of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. Nonalcoholic Fatty Liver Disease - An Update 2019. [DOI: 10.5772/intechopen.85780] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 124 |
Zhang X, Wong GL, Wong VW. Application of transient elastography in nonalcoholic fatty liver disease. Clin Mol Hepatol 2020;26:128-41. [PMID: 31696690 DOI: 10.3350/cmh.2019.0001n] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 125 |
Teeratorn N, Piyachaturawat P, Thanapirom K, Chaiteerakij R, Sonsiri K, Komolmit P, Tangkijvanich P, Rerknimitr R, Adams L, Treeprasertsuk S. Screening for non-alcoholic fatty liver disease in community setting: A cohort study using controlled attenuation parameter-transient elastography.JGH Open. 2020;4:245-250. [PMID: 32280772 DOI: 10.1002/jgh3.12252] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 126 |
Perazzo H, Cardoso SW, Yanavich C, Nunes EP, Morata M, Gorni N, da Silva PS, Cardoso C, Almeida C, Luz P, Veloso VG, Grinsztejn B. Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy. J Int AIDS Soc. 2018;21:e25201. [PMID: 30394678 DOI: 10.1002/jia2.25201] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 127 |
Arrese M, Barrera F, Triantafilo N, Arab JP. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. Expert Rev Gastroenterol Hepatol 2019;13:849-66. [PMID: 31353974 DOI: 10.1080/17474124.2019.1649981] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 128 |
Xia MF, Bian H, Gao X. NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment. Front Pharmacol. 2019;10:877. [PMID: 31447675 DOI: 10.3389/fphar.2019.00877] [Cited by in Crossref: 48] [Cited by in F6Publishing: 57] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 129 |
Xiong M, Li J, Yang S, Zeng F, Ji Y, Liu J, Wu Q, He Q, Tang X, Jiang R, Zhou F, Chen Y, Wen W, Chen J, Hou J. Impacts of cigarette smoking on liver fibrosis and its regression under therapy in male patients with chronic hepatitis B. Liver Int 2019;39:1428-36. [PMID: 30920714 DOI: 10.1111/liv.14108] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 130 |
Boyle M, Tiniakos D, Schattenberg JM, Ratziu V, Bugianessi E, Petta S, Oliveira CP, Govaere O, Younes R, McPherson S, Bedossa P, Nielsen MJ, Karsdal M, Leeming D, Kendrick S, Anstee QM. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Rep 2019;1:188-98. [PMID: 32039369 DOI: 10.1016/j.jhepr.2019.06.004] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 14.3] [Reference Citation Analysis]
|
| 131 |
Alferink LJM, Trajanoska K, Erler NS, Schoufour JD, de Knegt RJ, Ikram MA, Janssen HLA, Franco OH, Metselaar HJ, Rivadeneira F, Darwish Murad S. Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution. J Bone Miner Res 2019;34:1254-63. [PMID: 31074909 DOI: 10.1002/jbmr.3713] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 132 |
Gheibi S, Gouvarchin Ghaleh HE, Motlagh BM, Azarbayjani AF, Zarei L. Therapeutic effects of curcumin and ursodexycholic acid on non-alcoholic fatty liver disease. Biomed Pharmacother 2019;115:108938. [PMID: 31071511 DOI: 10.1016/j.biopha.2019.108938] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 133 |
Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J Mol Sci 2019;20:E1948. [PMID: 31010049 DOI: 10.3390/ijms20081948] [Cited by in Crossref: 90] [Cited by in F6Publishing: 97] [Article Influence: 22.5] [Reference Citation Analysis]
|
| 134 |
Watt GP, Lee M, Pan JJ, Fallon MB, Loomba R, Beretta L, McCormick JB, Fisher-Hoch SP. High Prevalence of Hepatic Fibrosis, Measured by Elastography, in a Population-Based Study of Mexican Americans. Clin Gastroenterol Hepatol 2019;17:968-975.e5. [PMID: 29902644 DOI: 10.1016/j.cgh.2018.05.046] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 135 |
Lonardo A, Lugari S, Ballestri S, Nascimbeni F, Baldelli E, Maurantonio M. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue? Acta Diabetol 2019;56:385-96. [PMID: 30519965 DOI: 10.1007/s00592-018-1266-0] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 14.3] [Reference Citation Analysis]
|
| 136 |
Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019;156:1264-1281.e4. [PMID: 30660725 DOI: 10.1053/j.gastro.2018.12.036] [Cited by in Crossref: 619] [Cited by in F6Publishing: 637] [Article Influence: 154.8] [Reference Citation Analysis]
|
| 137 |
Moore JB. From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis. Proc Nutr Soc. 2019;78:290-304. [PMID: 30924429 DOI: 10.1017/s0029665119000570] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 138 |
Kao W, Su C, Fang S, Tang J, Chang C, Liu J. Determination of the predictive factors for significant liver fibrosis assessed through transient elastography. Adv Dig Med 2019;6:5-14. [DOI: 10.1002/aid2.13102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 139 |
Tsochatzis EA, Newsome PN. Non-alcoholic fatty liver disease and the interface between primary and secondary care. Lancet Gastroenterol Hepatol 2018;3:509-17. [PMID: 29893235 DOI: 10.1016/S2468-1253(18)30077-3] [Cited by in Crossref: 74] [Cited by in F6Publishing: 80] [Article Influence: 18.5] [Reference Citation Analysis]
|
| 140 |
Li B, Zhang L, Zhang Z, Yan G, Zhu L, Lu W, Yu H. A noninvasive indicator for the diagnosis of early hepatitis B virus-related liver fibrosis. Eur J Gastroenterol Hepatol 2019;31:218-23. [PMID: 30277926 DOI: 10.1097/MEG.0000000000001281] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 141 |
Mu W, Cheng XF, Liu Y, Lv QZ, Liu GL, Zhang JG, Li XY. Potential Nexus of Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Insulin Resistance Between Hepatic and Peripheral Tissues. Front Pharmacol 2018;9:1566. [PMID: 30692925 DOI: 10.3389/fphar.2018.01566] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 142 |
Israelsen M, Krag A, Thiele M. Clinical Aspects of Alcoholic Liver Disease. The Human Gut-Liver-Axis in Health and Disease 2019. [DOI: 10.1007/978-3-319-98890-0_1] [Reference Citation Analysis]
|
| 143 |
Bazerbachi F, Haffar S, Wang Z, Cabezas J, Arias-Loste MT, Crespo J, Darwish-Murad S, Ikram MA, Olynyk JK, Gan E, Petta S, Berzuini A, Prati D, de Lédinghen V, Wong VW, Del Poggio P, Chávez-Tapia NC, Chen YP, Cheng PN, Yuen MF, Das K, Chowdhury A, Caballeria L, Fabrellas N, Ginès P, Kumar M, Sarin SK, Conti F, Andreone P, Sirli R, Cortez-Pinto H, Carvalhana S, Sugihara T, Kim SU, Parikh P, Chayama K, Corpechot C, Kim KM, Papatheodoridis G, Alsebaey A, Kamath PS, Murad MH, Watt KD. Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. Clin Gastroenterol Hepatol 2019;17:54-64.e1. [PMID: 30196155 DOI: 10.1016/j.cgh.2018.08.069] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 144 |
Hamed AE, Elsahar M, Elwan NM, El-Nakeep S, Naguib M, Soliman HH, Ahmed Aboubakr A, AbdelMaqsod A, Sedrak H, Assaad SN, Elwakil R, Esmat G, Salh S, Mostafa T, Mogawer S, Sadek SE, Saber MM, Ezelarab H, Mahmoud AA, Sultan S, El Kassas M, Kamal E, ElSayed NM, Moussa S. Managing diabetes and liver disease association. Arab J Gastroenterol 2018;19:166-79. [PMID: 30420265 DOI: 10.1016/j.ajg.2018.08.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 145 |
Allen AM, Van Houten HK, Sangaralingham LR, Talwalkar JA, McCoy RG. Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database. Hepatology 2018;68:2230-8. [PMID: 29774589 DOI: 10.1002/hep.30094] [Cited by in Crossref: 70] [Cited by in F6Publishing: 75] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 146 |
Petta S, Di Marco V, Pipitone RM, Grimaudo S, Buscemi C, Craxì A, Buscemi S. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population. Liver Int 2018;38:2060-8. [PMID: 29577560 DOI: 10.1111/liv.13743] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 12.4] [Reference Citation Analysis]
|
| 147 |
Bril F, McPhaul MJ, Caulfield MP, Castille JM, Poynard T, Soldevila-Pico C, Clark VC, Firpi-Morell RJ, Lai J, Cusi K. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. J Investig Med 2019;67:303-11. [PMID: 30309884 DOI: 10.1136/jim-2018-000864] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
|
| 148 |
Shimizu M, Suzuki K, Kato K, Jojima T, Iijima T, Murohisa T, Iijima M, Takekawa H, Usui I, Hiraishi H, Aso Y. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab 2019;21:285-92. [DOI: 10.1111/dom.13520] [Cited by in Crossref: 150] [Cited by in F6Publishing: 157] [Article Influence: 30.0] [Reference Citation Analysis]
|
| 149 |
Guss D, Sherigar J, Mohanty SR. Missed Diagnosis of Liver Cirrhosis Leads to Disparities in Care for Older Patients. Gastroenterology Res 2018;11:333-9. [PMID: 30344803 DOI: 10.14740/gr1074w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 150 |
Buckley AJ, Thomas EL, Lessan N, Trovato FM, Trovato GM, Taylor-robinson SD. Non-alcoholic fatty liver disease: Relationship with cardiovascular risk markers and clinical endpoints. Diabetes Research and Clinical Practice 2018;144:144-52. [DOI: 10.1016/j.diabres.2018.08.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 151 |
Rowe IA. Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol 2018;3:66-72. [PMID: 29254617 DOI: 10.1016/S2468-1253(17)30142-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 152 |
Patel PJ, Banh X, Horsfall LU, Hayward KL, Hossain F, Johnson T, Stuart KA, Brown NN, Saad N, Clouston A, Irvine KM, Russell AW, Valery PC, Williams S, Powell EE. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. Intern Med J 2018;48:144-51. [PMID: 29083080 DOI: 10.1111/imj.13667] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 11.6] [Reference Citation Analysis]
|
| 153 |
Mustapic S, Ziga S, Matic V, Bokun T, Radic B, Lucijanic M, Marusic S, Babic Z, Grgurevic I. Ultrasound Grade of Liver Steatosis Is Independently Associated with the Risk of Metabolic Syndrome. Can J Gastroenterol Hepatol 2018;2018:8490242. [PMID: 30211140 DOI: 10.1155/2018/8490242] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 154 |
Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol 2018;24:3361-73. [PMID: 30122876 DOI: 10.3748/wjg.v24.i30.3361] [Cited by in CrossRef: 288] [Cited by in F6Publishing: 294] [Article Influence: 57.6] [Reference Citation Analysis]
|
| 155 |
Patel P, Hossain F, Horsfall LU, Banh X, Hayward KL, Williams S, Johnson T, Bernard A, Brown NN, Lampe G, Buck L, Saad N, Russell AW, Valery PC, Irvine KM, Clouston AD, Stuart KA, Rosenberg W, Powell EE. A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At-Risk Populations in Primary Care. Hepatol Commun 2018;2:893-905. [PMID: 30094401 DOI: 10.1002/hep4.1208] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 156 |
Li B, Zhang C, Zhan YT. Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. Can J Gastroenterol Hepatol 2018;2018:2784537. [PMID: 30065915 DOI: 10.1155/2018/2784537] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 11.2] [Reference Citation Analysis]
|
| 157 |
Caballería L, Pera G, Arteaga I, Rodríguez L, Alumà A, Morillas RM, de la Ossa N, Díaz A, Expósito C, Miranda D, Sánchez C, Prats RM, Urquizu M, Salgado A, Alemany M, Martinez A, Majeed I, Fabrellas N, Graupera I, Planas R, Ojanguren I, Serra M, Torán P, Caballería J, Ginès P. High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population-Based Study. Clin Gastroenterol Hepatol 2018;16:1138-1145.e5. [PMID: 29452268 DOI: 10.1016/j.cgh.2017.12.048] [Cited by in Crossref: 140] [Cited by in F6Publishing: 141] [Article Influence: 28.0] [Reference Citation Analysis]
|
| 158 |
Aller R, Fernández-rodríguez C, lo Iacono O, Bañares R, Abad J, Carrión JA, García-monzón C, Caballería J, Berenguer M, Rodríguez-perálvarez M, Miranda JL, Vilar-gómez E, Crespo J, García-cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterología y Hepatología (English Edition) 2018;41:328-49. [DOI: 10.1016/j.gastre.2018.05.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 159 |
Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterol Hepatol 2018;41:328-49. [PMID: 29631866 DOI: 10.1016/j.gastrohep.2017.12.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 160 |
Snyder HS, Sakaan SA, March KL, Siddique O, Cholankeril R, Cummings CD, Gadiparthi C, Satapathy SK, Ahmed A, Cholankeril G. Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies. J Clin Transl Hepatol. 2018;6:168-174. [PMID: 29951362 DOI: 10.14218/jcth.2017.00050] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 161 |
Harman DJ, Ryder SD, James MW, Wilkes EA, Card TR, Aithal GP, Guha IN. Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography. Aliment Pharmacol Ther 2018;47:504-15. [PMID: 29210096 DOI: 10.1111/apt.14463] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 162 |
Castera L. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough. Liver Int 2018;38 Suppl 1:67-70. [PMID: 29427494 DOI: 10.1111/liv.13658] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 163 |
Lindenmeyer CC, McCullough AJ. The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View. Clin Liver Dis 2018;22:11-21. [PMID: 29128051 DOI: 10.1016/j.cld.2017.08.003] [Cited by in Crossref: 142] [Cited by in F6Publishing: 145] [Article Influence: 28.4] [Reference Citation Analysis]
|
| 164 |
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328-57. [PMID: 28714183 DOI: 10.1002/hep.29367] [Cited by in Crossref: 3544] [Cited by in F6Publishing: 3493] [Article Influence: 708.8] [Reference Citation Analysis]
|
| 165 |
Cusi K. Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes. Contemporary Diabetes 2018. [DOI: 10.1007/978-3-319-61013-9_4] [Reference Citation Analysis]
|
| 166 |
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11-20. [PMID: 28930295 DOI: 10.1038/nrgastro.2017.109] [Cited by in Crossref: 2383] [Cited by in F6Publishing: 2269] [Article Influence: 476.6] [Reference Citation Analysis]
|
| 167 |
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018;67:123-33. [PMID: 28802062 DOI: 10.1002/hep.29466] [Cited by in Crossref: 1028] [Cited by in F6Publishing: 1058] [Article Influence: 205.6] [Reference Citation Analysis]
|
| 168 |
Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol 2018;53:362-76. [PMID: 29247356 DOI: 10.1007/s00535-017-1415-1] [Cited by in Crossref: 366] [Cited by in F6Publishing: 379] [Article Influence: 73.2] [Reference Citation Analysis]
|
| 169 |
Yang H, Park C. Glucose-Lowering Agents in the Management of Nonalcoholic Fatty Liver Disease. J Korean Diabetes 2018;19:88. [DOI: 10.4093/jkd.2018.19.2.88] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 170 |
Hardy T, Mcpherson S. Imaging-Based Assessment of Steatosis, Inflammation and Fibrosis in NAFLD. Curr Hepatology Rep 2017;16:298-307. [DOI: 10.1007/s11901-017-0368-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 171 |
Roulot D, Roudot-Thoraval F, NKontchou G, Kouacou N, Costes JL, Elourimi G, Le Clesiau H, Ziol M, Beaugrand M. Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan. Liver Int 2017;37:1897-906. [PMID: 28556413 DOI: 10.1111/liv.13481] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 172 |
Augustin S, Graupera I, Caballeria J. Non-alcoholic fatty liver disease: A poorly known pandemic. Medicina Clínica (English Edition) 2017;149:542-548. [DOI: 10.1016/j.medcle.2017.11.009] [Reference Citation Analysis]
|
| 173 |
Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi LE. Nonalcoholic fatty liver disease: Evolving paradigms. World J Gastroenterol 2017; 23(36): 6571-6592 [PMID: 29085206 DOI: 10.3748/wjg.v23.i36.6571] [Cited by in CrossRef: 110] [Cited by in F6Publishing: 115] [Article Influence: 18.3] [Reference Citation Analysis]
|
| 174 |
Alferink LJM, Fittipaldi J, Kiefte-de Jong JC, Taimr P, Hansen BE, Metselaar HJ, Schoufour JD, Ikram MA, Janssen HLA, Franco OH, Darwish Murad S. Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: The Rotterdam study. J Hepatol 2017;67:339-48. [PMID: 28578837 DOI: 10.1016/j.jhep.2017.03.013] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 8.2] [Reference Citation Analysis]
|
| 175 |
Augustin S, Graupera I, Caballeria J; en nombre del grupo de trabajo sobre «Hígado graso no alcohólico» de la Societat Catalana de Digestologia. Non-alcoholic fatty liver disease: A poorly known pandemic. Med Clin (Barc) 2017;149:542-8. [PMID: 28751080 DOI: 10.1016/j.medcli.2017.06.026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 176 |
McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, Oliveira CP, Francque S, Van Gaal L, Schattenberg JM, Tiniakos D, Burt A, Bugianesi E, Ratziu V, Day CP, Anstee QM. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. Am J Gastroenterol 2017;112:740-51. [PMID: 27725647 DOI: 10.1038/ajg.2016.453] [Cited by in Crossref: 358] [Cited by in F6Publishing: 337] [Article Influence: 59.7] [Reference Citation Analysis]
|
| 177 |
Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Dig Liver Dis 2017;49:471-83. [PMID: 28215516 DOI: 10.1016/j.dld.2017.01.147] [Cited by in Crossref: 201] [Cited by in F6Publishing: 194] [Article Influence: 33.5] [Reference Citation Analysis]
|
| 178 |
Cheng BC, Yen YH, Chen JF, Wu CK, Chang KC, Tseng PL, Tsai MC, Lin MT, Lin JT, Chen JB, Hu TH. Transient elastography as a screening tool for liver fibrosis in a large hemodialysis population. Sci Rep 2017;7:46458. [PMID: 28422172 DOI: 10.1038/srep46458] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 179 |
Lazaridis N, Tsochatzis E. Current and future treatment options in non-alcoholic steatohepatitis (NASH). Expert Rev Gastroenterol Hepatol 2017;11:357-69. [PMID: 28276821 DOI: 10.1080/17474124.2017.1293523] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 180 |
Sunny NE, Bril F, Cusi K. Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. Trends Endocrinol Metab 2017;28:250-60. [PMID: 27986466 DOI: 10.1016/j.tem.2016.11.006] [Cited by in Crossref: 192] [Cited by in F6Publishing: 181] [Article Influence: 32.0] [Reference Citation Analysis]
|
| 181 |
Wainwright P, Scorletti E, Byrne CD. Type 2 Diabetes and Hepatocellular Carcinoma: Risk Factors and Pathogenesis. Curr Diab Rep 2017;17. [DOI: 10.1007/s11892-017-0851-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 182 |
Käräjämäki AJ, Kettunen O, Lepojärvi S, Koivurova OP, Kesäniemi YA, Huikuri H, Ukkola O. Presence of atrial fibrillation is associated with liver stiffness in an elderly Finnish population. PLoS One 2017;12:e0173855. [PMID: 28288202 DOI: 10.1371/journal.pone.0173855] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 183 |
van Asten M, Verhaegh P, Koek G, Verbeek J. The increasing burden of NAFLD fibrosis in the general population: Time to bridge the gap between hepatologists and primary care. Hepatology 2017;65:1078. [PMID: 27862126 DOI: 10.1002/hep.28940] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 184 |
Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med 2017;15:45. [PMID: 28241825 DOI: 10.1186/s12916-017-0806-8] [Cited by in Crossref: 262] [Cited by in F6Publishing: 253] [Article Influence: 43.7] [Reference Citation Analysis]
|
| 185 |
Martini A, Ceranto E, Gatta A, Angeli P, Pontisso P. Occult liver disease burden: Analysis from a large general practitioners' database. United European Gastroenterol J 2017;5:982-6. [PMID: 29163964 DOI: 10.1177/2050640617696402] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 186 |
Thiele M, Madsen BS, Krag A. Is liver stiffness equal to liver fibrosis? Hepatology 2017;65:749. [PMID: 27596963 DOI: 10.1002/hep.28791] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 187 |
Darwish Murad S, Koehler EM, Plompen EP, Janssen HL. Reply. Hepatology 2017;65:749-50. [PMID: 27596712 DOI: 10.1002/hep.28789] [Reference Citation Analysis]
|
| 188 |
Zelber-Sagi S, Shoham D, Zvibel I, Abu-Abeid S, Shibolet O, Fishman S. Predictors for advanced fibrosis in morbidly obese non-alcoholic fatty liver patients. World J Hepatol 2017;9:91-8. [PMID: 28144390 DOI: 10.4254/wjh.v9.i2.91] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 189 |
Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 2017;14:32-42. [PMID: 27729660 DOI: 10.1038/nrgastro.2016.147] [Cited by in Crossref: 505] [Cited by in F6Publishing: 483] [Article Influence: 84.2] [Reference Citation Analysis]
|
| 190 |
Wang JH, Yen YH, Yao CC, Hung CH, Chen CH, Hu TH, Lee CM, Lu SN. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy. Liver Int 2016;36:1793-9. [PMID: 27254286 DOI: 10.1111/liv.13179] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 191 |
Conti F, Vukotic R, Foschi FG, Domenicali M, Giacomoni P, Savini S, Lanzi A, Dall'Aglio AC, Saini G, Matroroberto M, Bernardi M, Stefanini GF, Andreone P. Transient elastography in healthy subjects and factors influencing liver stiffness in non-alcoholic fatty liver disease: An Italian community-based population study. Dig Liver Dis 2016;48:1357-63. [PMID: 27522549 DOI: 10.1016/j.dld.2016.07.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 192 |
Ginès P, Graupera I, Lammert F, Angeli P, Caballeria L, Krag A, Guha IN, Murad SD, Castera L. Screening for liver fibrosis in the general population: a call for action. The Lancet Gastroenterology & Hepatology 2016;1:256-60. [DOI: 10.1016/s2468-1253(16)30081-4] [Cited by in Crossref: 94] [Cited by in F6Publishing: 81] [Article Influence: 13.4] [Reference Citation Analysis]
|
| 193 |
Bril F, Cusi K. Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus. Endocrinol Metab Clin North Am 2016;45:765-81. [PMID: 27823604 DOI: 10.1016/j.ecl.2016.06.005] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 194 |
Varbobitis IC, Siakavellas SI, Koutsounas IS, Karagiannakis DS, Ioannidou P, Papageorgiou MV, Pavlopoulou ID, Schizas D, Bamias G, Vlachogiannakos I, Ladas SD, Papatheodoridis GV. Reliability and applicability of two-dimensional shear-wave elastography for the evaluation of liver stiffness. Eur J Gastroenterol Hepatol 2016;28:1204-9. [PMID: 27340898 DOI: 10.1097/MEG.0000000000000686] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 195 |
van Meer S, van Erpecum KJ, Sprengers D, Klümpen HJ, Jansen PL, Ijzermans JN, Siersema PD, de Man RA, Verheij J. Hepatocellular carcinoma in noncirrhotic livers is associated with steatosis rather than steatohepatitis: potential implications for pathogenesis. Eur J Gastroenterol Hepatol 2016;28:955-62. [PMID: 27196679 DOI: 10.1097/MEG.0000000000000641] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 196 |
Chin JL, Pavlides M, Moolla A, Ryan JD. Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? Front Pharmacol. 2016;7:159. [PMID: 27378924 DOI: 10.3389/fphar.2016.00159] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 197 |
Cusi K. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia 2016;59:1112-20. [PMID: 27101131 DOI: 10.1007/s00125-016-3952-1] [Cited by in Crossref: 93] [Cited by in F6Publishing: 95] [Article Influence: 13.3] [Reference Citation Analysis]
|
| 198 |
Barb D, Portillo-Sanchez P, Cusi K. Pharmacological management of nonalcoholic fatty liver disease. Metabolism. 2016;65:1183-1195. [PMID: 27301803 DOI: 10.1016/j.metabol.2016.04.004] [Cited by in Crossref: 70] [Cited by in F6Publishing: 75] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 199 |
Portillo-Sanchez P, Cusi K. Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus. Clin Diabetes Endocrinol 2016;2:9. [PMID: 28702244 DOI: 10.1186/s40842-016-0027-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 200 |
Jiao J, Watt GP, Lee M, Rahbar MH, Vatcheva KP, Pan JJ, McCormick JB, Fisher-Hoch SP, Fallon MB, Beretta L. Cirrhosis and Advanced Fibrosis in Hispanics in Texas: The Dominant Contribution of Central Obesity. PLoS One 2016;11:e0150978. [PMID: 26950933 DOI: 10.1371/journal.pone.0150978] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 201 |
Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Lonardo A. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. Adv Ther 2016;33:291-319. [PMID: 26921205 DOI: 10.1007/s12325-016-0306-9] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 8.4] [Reference Citation Analysis]
|
| 202 |
Cheng PN, Chiu YC, Chiu HC, Chien SC. The Application of Liver Stiffness Measurement in Residents Without Overt Liver Diseases Through a Community-Based Screening Program. Medicine (Baltimore) 2016;95:e3193. [PMID: 27015215 DOI: 10.1097/MD.0000000000003193] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 203 |
Kim JM, Ha SY, Joh JW, Sinn DH, Jeong WK, Choi GS, Gwak GY, Kwon CHD, Kim YK, Paik YH, Lee JH, Lee WJ, Lee SK, Park CK. Predicting Hepatic Steatosis in Living Liver Donors via Noninvasive Methods. Medicine (Baltimore) 2016;95:e2718. [PMID: 26886612 DOI: 10.1097/MD.0000000000002718] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 204 |
Wang Y, Hou J. Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools. Hepatol Int 2016;10:448-61. [DOI: 10.1007/s12072-015-9695-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 205 |
Ahmed A, Perumpail RB, Harrison SA. High prevalence of hepatic fibrosis in the setting of coexisting diabetes and hepatic steatosis: A case for selective screening in the general population? Hepatology 2016;63:20-2. [PMID: 26452752 DOI: 10.1002/hep.28277] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 206 |
Schepis F, Villa E. Thrombophilic genetic risk factors for liver fibrosis: To screen or not to screen? J Hepatol 2015;63:1311-3. [PMID: 26434395 DOI: 10.1016/j.jhep.2015.09.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
